Drug intelligence / Profile preview

CC49-VS-MMAE

Development stage: Discontinued
Lead developer: City of Hope
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**CC49-VS-MMAE** is an experimental, preclinical antibody-drug conjugate directed against **tumor-associated glycoprotein 72**. It consists of the murine anti-TAG72 monoclonal antibody CC49 conjugated through reduced hinge-region disulfides to the microtubule-disrupting payload monomethyl auristatin E using a vinylsulfone linker. The construct was evaluated in ovarian cancer models at City of Hope, but was not further studied because its low drug-to-antibody ratio of approximately 2.3 was considered unfavorable relative to alternative CC49-MMAE linker constructs.

Other names: CC49-VS-MMAECC-49-VS-MMAECC 49-VS-MMAE

Targets

TUBB (Tubulin (alpha and beta subunits))TAG-72

Beyond the preview

Go deeper on CC49-VS-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC49-VS-MMAE.

Explore the full profile